<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160701</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00098021</org_study_id>
    <nct_id>NCT05160701</nct_id>
  </id_info>
  <brief_title>Bringing Health Home</brief_title>
  <acronym>BHH</acronym>
  <official_title>Bringing Health Home: Evaluation of a Residential-based Telehealth Care Coordination Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Individuals suffering from Serious Mental Illnesses (SMI) are at risk for serious adverse&#xD;
      health and social outcomes compared to the general population due to a high prevalence of&#xD;
      chronic physical health disorders such as cardiovascular disease, hypertension, and Type II&#xD;
      Diabetes, along with consequences of mental distress such as suicide, substance abuse, and&#xD;
      acute stress.While pharmacological treatments exist for these conditions, they have limited&#xD;
      effectiveness in SMI populations because: (1) up to 60% of individuals with SMI do not take&#xD;
      their psychiatric or somatic medications as prescribed, (2) individuals with SMI have poorer&#xD;
      clinical outcomes and experience high rates of hospitalizations, and (3) individuals with SMI&#xD;
      experience worse care. Challenges in the management of these complex chronic health and&#xD;
      mental health conditions have led to the development of intensive community-based service&#xD;
      delivery programs. However, as currently structured these intensive in-person interventions&#xD;
      have only had limited impact optimizing service delivery, and consequently on adherence to&#xD;
      treatment and health outcomes. While in-person clinical contact in select situations is&#xD;
      important, telehealth may serve as an effective and nimble intervention to help meet the high&#xD;
      need for clinical intervention for SMI populations and particularly those with geographically&#xD;
      limited-service access. Although research exists regarding the efficacy of telehealth with&#xD;
      SMI populations, most of the existing interventions with this population have been designed&#xD;
      for institutional settings, not community settings, because of barriers to adoption of&#xD;
      telehealth such as limited access to digital technology, technical support difficulties and&#xD;
      cost of necessary technology. The COVID-19 pandemic has underscored the need for developing&#xD;
      effective telemedicine and telemonitoring technologies to serve the unique needs of this&#xD;
      vulnerable population in community settings. This project builds on a successful Phase I SBIR&#xD;
      project and ongoing Phase II clinical trial of the Medherent medication management platform.&#xD;
      This study will test an expanded set of telehealth care-coordination services that can be&#xD;
      used to address the broad health needs of individuals diagnosed with SMI living in community&#xD;
      settings and supported by community mental health agencies. The study team will recruit 300&#xD;
      individuals, including 200 individuals currently using the device and 100 new users of the&#xD;
      device. The study will test the existing Medherent platform and a set of extended services.&#xD;
      Our key outcomes include acute service use, receipt of preventive and other health&#xD;
      screenings, health outcomes and costs of services. The study will use a Stepped Wedge Design&#xD;
      approach with a matched comparison group to identify potential benefits of the intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>To test our research aims we will use a stepped wedge cluster randomized design (SWD) and matched control group. All enrolled individuals will be grouped into a rollout unit. This unit could be comprised of individuals living in a group home or multiple group homes, a group of clients served by a case manager at an agency or a division of an agency. We anticipate that units will have approximately 10 - 15 clients and that we will have approximately 25 units across participating agencies. This design allows the study team to address problems with the rollout of the machines facilitating a good phase-in of the intervention for each unit. Third, this design addresses issues associated with the diffusion of the intervention within agencies that would occur with individual randomization while maintaining strong internal validity and assessment of the treatment effect.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Health Service Utilization</measure>
    <time_frame>Two years prior to study enrollment to at least one year after study enrollment.</time_frame>
    <description>The study team will use medical records and claims data to calculate monthly counts of outpatient/ambulatory care events, inpatient hospitalization, and Emergency Room or urgent care visits. The Healthcare Effectiveness Data and Information Set (HEDIS) tool will be used to identify preventable hospitalization or emergency room visits, follow up care after hospitalizations or emergency room visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Consumer Satisfaction STAR-P</measure>
    <time_frame>Change from Baseline to 6 months to 12 Months</time_frame>
    <description>Consumers self reports of services satisfaction with agency services. Scale is between 12 and 60. Higher scores are associated with higher satisfaction with services.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diabetes control as reported hemoglobin A1c levels</measure>
    <time_frame>Two years prior to study enrollment to at least one year after study enrollment.</time_frame>
    <description>Reported hemoglobin A1c will be use to assess adherence to medication by modeling individual change change over time. A1C levels between 5.7 and less than 6.5% will be conferred as prediabetes range. A1C level of 6.5% or higher are considered in the diabetes range.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reported Low-density lipoprotein (LDL)/High-density lipoprotein (HDL)</measure>
    <time_frame>Two years prior to study enrollment to at least one year after study enrollment.</time_frame>
    <description>Reported Low-density lipoprotein (LDL)/High-density lipoprotein (HDL) will be use to assess adherence to medication by modeling individual change change over time. Normal HDL is 45 to 70 mg/dL for men and 50 to 90 mg/dL for women. The cutoff for good total cholesterol to HDL ratio is 5:1. Lower ratios are better than higher ratios.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High blood pressure.</measure>
    <time_frame>Two years prior to study enrollment to at least one year after study enrollment.</time_frame>
    <description>Reported blood pressure will be use to assess adherence to medication by modeling individual change change over time. Scores will be considered normal if systolic is less than 120 mm Hg and diastolic less than 80 mm Hg. Scores will be considered elevated if systolic is 120-129 mm Hg and diastolic is less than 80 mm Hg. Scores will be considered evidence of hypertension if systolic is greater than 130 mm Hg and diastolic is more than 80 mm Hg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Health Service Costs</measure>
    <time_frame>Two years prior to study enrollment to at least one year after study enrollment.</time_frame>
    <description>Costs of health services and mental health agency care will be calculated from Medicaid Claims data. These costs will be calculated for outpatient care, emergency room/urgent care, and inpatient hospitalization care by summing up all the costs of medical claims in each of these categories by month.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Mental Disorders, Severe</condition>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual Care: no intervention elements.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Existing Medherent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group using the Medherent Device with no added intervention components.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New Medherent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group using Medherent Device with added interventional components.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medherent</intervention_name>
    <description>Medherent is a telehealth adherence intervention platform designed for individuals with Serious Mental Illness living in the community. It is currently being used to dispense medication and monitor consumer adherence. It is a fully supported digital hub that is always on network connection and provides a cost- effective mechanism for increased care coordination through the Electronic Medication Record (EMR). The enhanced intervention will add collection of health data though Bluetooth connected devices, Telehealth medical visits and integrated algorithms that provide feed back to providers and consumers about health status.</description>
    <arm_group_label>Existing Medherent</arm_group_label>
    <arm_group_label>New Medherent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Serious Mental Illness Diagnosis&#xD;
&#xD;
          -  Prescribed psychiatric medications&#xD;
&#xD;
          -  18 to 80 years old&#xD;
&#xD;
          -  Receives services by a participating community mental health agency at time of&#xD;
             enrollment&#xD;
&#xD;
          -  Be unable to consent to the study as assessed by the consent questionnaire.&#xD;
&#xD;
          -  Sample 1: Current Users of Medherent or&#xD;
&#xD;
          -  Sample 2: Willing or able to authorize to have the Medherent device in your residence&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ Unable to have the Medherent device in residence&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>George Unick, PhD</last_name>
    <phone>4107063735</phone>
    <email>junick@ssw.umaryland.edu</email>
  </overall_contact>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>George Unick</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

